查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606456

2 型糖尿病市場，按藥物類別、按給藥途徑、按配銷通路、按最終用戶、按國家和地區分類 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Type 2 Diabetes Market, By Drug Class, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年第二型糖尿病市場規模為348.4909億美元，2024年至2032年複合年成長率為8.40%。

2 型糖尿病市場-市場動態

全球 2 型糖尿病盛行率不斷上升，推動市場需求

全球第2型糖尿病發生率上升主要是由於生活方式的改變，人口老化是推動第2型糖尿病市場成長的主要因素。根據世界衛生組織 (WHO) 的數據，超過 95% 的糖尿病患者患有第 2 型糖尿病。此外，全球肥胖和超重人群的增加與第 2 型糖尿病發病率上升密切相關，因為體重過重會顯著增加胰島素阻抗。儘管設備成本高昂，儘管藥物取得了進步，但許多患者並不了解新型糖尿病藥物，這限制了它們的採用並減緩了市場成長。相反，胰高血糖素樣胜肽 1 受體激動劑（Tanzeum、Trulicity）和鈉葡萄糖協同轉運蛋白 2 抑制劑（Jardiance）等藥物開發預計將為 2 型糖尿病市場創造巨大的成長機會。

2 型糖尿病市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 8.40% 左右的複合年成長率成長

根據藥物類別細分，鈉-葡萄糖協同轉運蛋白 2 (SGLT2) 抑制劑預計將在 2023 年顯示最大的市場佔有率

根據給藥途徑細分，口服是2023年的主導細分市場

根據最終用戶細分，家庭護理是 2023 年的領先細分市場

按地區分類，北美 2 型糖尿病市場是 2023 年的主要收入來源

2 型糖尿病市場細分分析：

全球 2 型糖尿病市場根據藥物類別、給藥途徑、配銷通路、最終用戶和地區進行細分。

根據藥物類別，市場分為四類：二肽基肽酶 4 抑制劑、鈉-葡萄糖協同轉運蛋白 2 (SGLT2) 抑制劑、胰高血糖素樣胜肽 1 受體激動劑等。鈉-葡萄糖協同轉運蛋白 2 (SGLT2) 領域在市場上佔據主導地位。這主要是由於它們能夠有效降低血糖並降低心血管和腎臟事件的風險。

根據配銷通路，市場分為三類：網路藥局、零售藥局和醫院藥局。預計線上產業在預測期內將以最高的複合年成長率成長。這主要是因為對方便獲得糖尿病藥物的需求不斷成長，患者可以在家中輕鬆訂購處方，這使其成為許多人的首選。

2 型糖尿病市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區、中東和非洲地區。這些區域根據開展業務的國家進一步分類。

2 型糖尿病市場-競爭格局：

在疾病盛行率不斷上升以及對有效管理方案的需求不斷成長的推動下，全球 2 型糖尿病市場正在快速成長。該市場的競爭格局由國際和本地參與者組成，他們利用各種分銷管道，包括電子商務和零售合作夥伴關係。公司透過有競爭力的價格、產品品質和創新來脫穎而出。擴大市場佔有率的關鍵策略包括推出新產品、投資研發以及進行併購，所有這些都是為了滿足尋求有效糖尿病護理的患者不斷變化的需求。

最新進展：

2023 年 10 月，Glenmark Pharmaceuticals 宣布推出印度首個針對成人第 2 型糖尿病及合併症患者的三藥固定劑量組合 (FDC) 療法。該藥物名為 Zita DM，結合了三種藥物來增強血糖控制，幫助患者維持最佳血糖水平。這標誌著印度糖尿病管理的重大創新。

2024 年 6 月，FDA 批准阿斯特捷利康的 Farxiga（達格列淨）用於幫助控制 10 歲及以上患有第 2 型糖尿病的兒童的血糖值。此次批准基於 T2NOW III 期試驗的令人鼓舞的結果。 Farxiga 先前已被授權用於成人，除了飲食和運動外，還支援血糖管理。

目錄

第 1 章：2 型糖尿病市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的第 2 型糖尿病市場片段
    • 依給藥途徑分類的 2 型糖尿病市場片段
    • 按配銷通路分類的 2 型糖尿病市場片段
    • 最終用戶的第 2 型糖尿病市場片段
    • 按國家/地區分類的 2 型糖尿病市場片段
    • 按地區分類的第 2 型糖尿病市場片段
  • 競爭洞察

第 3 章：2 型糖尿病主要市場趨勢

  • 2 型糖尿病市場促進因素
    • 市場促進因素的影響分析
  • 2 型糖尿病市場限制
    • 市場限制影響分析
  • 2 型糖尿病市場機會
  • 2型糖尿病市場未來趨勢

第 4 章：2 型糖尿病產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：2 型糖尿病市場：地緣政治緊張局勢升級的影響

  • COVID-19 大流行的影響
  • 俄羅斯-烏克蘭戰爭的影響
  • 中東衝突的影響

第 6 章：2 型糖尿病市場格局

  • 2023 年第 2 型糖尿病市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：2 型糖尿病市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 二肽基肽酶 4 抑制劑
    • 鈉-葡萄糖協同轉運蛋白 (SGLT2) 抑制劑
    • 胰高血糖素樣胜肽 1 受體激動劑
    • 其他

第 8 章：2 型糖尿病市場 - 依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 注射用
    • 口服

第 9 章：2 型糖尿病市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 網路藥局
    • 零售藥局
    • 醫院藥房

第 10 章：2 型糖尿病市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院和診所
    • 家庭護理設置
    • 學術及研究機構
    • 其他

第 11 章：2 型糖尿病市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美 2 型糖尿病主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按配銷通路）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲第 2 型糖尿病主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按配銷通路）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區 2 型糖尿病主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按配銷通路）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲第 2 型糖尿病主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲 2 型糖尿病主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - 2 型糖尿病產業

  • 競爭儀表板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Eli Lilly and Company
    • Sanofi
    • Merck & Co., Inc.
    • AstraZeneca PLC
    • Boehringer Ingelheim
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Novartis AG
    • Roche Holding AG
    • Daiichi Sankyo Company, Limited
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma Limited
    • Lupin Limited
    • Medtronic
    • B. Braun Melsungen AG
    • F. Hoffmann-La Roche
    • Abbott Laboratories
    • Insulet Corporation
    • Torrent Pharmaceuticals Limited
    • Takeda Pharmaceuticals Limited
    • Acon Laboratories, Inc.
    • Akros Pharma
    • Adocia
    • Amgen
    • Bayer AG
    • Biocon
    • Becton, Dickson, and Company
    • Peptron
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4171

REPORT HIGHLIGHT

Type 2 diabetes market size was valued at USD 34,849.09 Million in 2023, expanding at a CAGR of 8.40% from 2024 to 2032.

Type 2 diabetes is a chronic metabolic disorder where the body either resists insulin or doesn't produce enough of it, leading to high blood sugar levels. Symptoms may be mild or unnoticed for years, with signs like increased thirst, frequent urination, fatigue, or tingling in the hands and feet. Diagnosis typically involves blood tests like fasting plasma glucose or the A1C test to assess average blood sugar levels.

Type 2 Diabetes Market- Market Dynamics

Increasing prevalence of type 2 diabetes across the globe to propel market demand

The rising incidence of type 2 diabetes among people worldwide is mainly due to the lifestyle changes and aging populations is the major factor driving the growth of the type 2 diabetes market. According to the World Health Organization (WHO), more than 95% of people with diabetes have type 2 diabetes. Besides, the global rise in obesity and overweight individuals is closely linked to higher rates of type 2 diabetes, as excess weight significantly increases insulin resistance. However high cost of devices and despite pharmaceutical advancements, many patients are unaware of novel diabetes drugs, limiting their adoption and slowing market growth. On the contrary, pharmaceutical developments, such as glucagon-like peptide-1 receptor agonists (Tanzeum, Trulicity) and sodium glucose cotransporter-2 inhibitors (Jardiance) are predicted to create massive growth opportunities for the type 2 diabetes market.

Type 2 Diabetes Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.40% over the forecast period (2024-2032)

Based on drug class segmentation, sodium-glucose cotransporter 2 (SGLT2) inhibitors was predicted to show maximum market share in the year 2023

Based on route of administration segmentation, oral was the leading segment in 2023

Based on end-user segmentation, homecare was the leading segment in 2023

On the basis of region, the North America type 2 diabetes market was the leading revenue generator in 2023

Type 2 Diabetes Market- Segmentation Analysis:

The Global Type 2 Diabetes Market is segmented on the basis of Drug Class, Route of Administration, Distribution Channel, End User, and Region.

The market is divided into four categories based on drug class: dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists, and others. The sodium-glucose cotransporter 2 (SGLT2) sector dominates the market. This is majorly owing to their effectiveness in lowering blood sugar and reducing the risk of cardiovascular and renal events.

The market is divided into three categories based on distribution channel: online pharmacies, retail pharmacies, and hospital pharmacies. The online sector is predicted to rise at the highest CAGR during the forecast period. This is mainly because the increasing demand for convenient access to diabetes medications allows patients to order prescriptions easily from home, making it a preferred option for many.

Type 2 Diabetes Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Type 2 Diabetes Market- Competitive Landscape:

The global type 2 diabetes market is rapidly growing, driven by the increasing prevalence of the disease and rising demand for effective management options. This market features a competitive landscape comprised of both international and local players who utilize various distribution channels, including e-commerce and retail partnerships. Companies differentiate themselves through competitive pricing, product quality, and innovation. Key strategies for expanding market share include launching new products, investing in research and development, and pursuing mergers and acquisitions, all aimed at meeting the evolving needs of patients seeking effective diabetes care.

Recent Developments:

In October 2023, Glenmark Pharmaceuticals announced the launch of India's first triple-drug fixed-dose combination (FDC) therapy for adults with Type 2 diabetes and comorbidities. Named Zita DM, the drug combines three medications to enhance glycemic control, helping patients maintain optimal blood glucose levels. This marks a significant innovation in diabetes management in India.

In June 2024, the FDA approved AstraZeneca's Farxiga (dapagliflozin) to help control blood sugar levels in children aged 10 and up with type 2 diabetes. This approval is based on encouraging findings from the T2NOW Phase III trial. Farxiga was previously authorized for adults, supporting blood sugar management alongside diet and exercise.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TYPE 2 DIABETES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • Daiichi Sankyo Company, Limited
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Lupin Limited
  • Medtronic
  • B. Braun Melsungen AG
  • F. Hoffmann-La Roche
  • Abbott Laboratories
  • Insulet Corporation
  • Torrent Pharmaceuticals Limited
  • Takeda Pharmaceuticals Limited
  • Acon Laboratories, Inc.
  • Akros Pharma
  • Adocia
  • Amgen
  • Bayer AG
  • Biocon
  • Becton, Dickson, and Company
  • Peptron
  • Others

GLOBAL TYPE 2 DIABETES MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Dipeptidyl Peptidase-4 Inhibitors
  • Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  • Glucagon-like Peptide 1 Receptor Agonists
  • Others

GLOBAL TYPE 2 DIABETES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Parenteral
  • Oral

GLOBAL TYPE 2 DIABETES MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

GLOBAL TYPE 2 DIABETES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Homecare Settings
  • Academic & Research Institutes
  • Others

GLOBAL TYPE 2 DIABETES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Type 2 Diabetes Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Type 2 Diabetes Market Snippet by Drug Class
    • 2.1.2. Type 2 Diabetes Market Snippet by Route of Administration
    • 2.1.3. Type 2 Diabetes Market Snippet by Distribution Channel
    • 2.1.4. Type 2 Diabetes Market Snippet by End User
    • 2.1.5. Type 2 Diabetes Market Snippet by Country
    • 2.1.6. Type 2 Diabetes Market Snippet by Region
  • 2.2. Competitive Insights

3. Type 2 Diabetes Key Market Trends

  • 3.1. Type 2 Diabetes Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Type 2 Diabetes Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Type 2 Diabetes Market Opportunities
  • 3.4. Type 2 Diabetes Market Future Trends

4. Type 2 Diabetes Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Type 2 Diabetes Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Type 2 Diabetes Market Landscape

  • 6.1. Type 2 Diabetes Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Type 2 Diabetes Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Dipeptidyl Peptidase-4 Inhibitors
    • 7.1.3. Sodium-glucose Cotransporter (SGLT2) Inhibitors
    • 7.1.4. Glucagon-like Peptide 1 Receptor Agonists
    • 7.1.5. Others

8. Type 2 Diabetes Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Parenteral
    • 8.1.3. Oral

9. Type 2 Diabetes Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Online Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Hospital Pharmacies

10. Type 2 Diabetes Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospitals & Clinics
    • 10.1.3. Homecare Settings
    • 10.1.4. Academic & Research Institutes
    • 10.1.5. Others

11. Type 2 Diabetes Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Type 2 Diabetes Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Type 2 Diabetes Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Type 2 Diabetes Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Type 2 Diabetes Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Type 2 Diabetes Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Type 2 Diabetes Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Eli Lilly and Company
    • 12.2.2. Sanofi
    • 12.2.3. Merck & Co., Inc.
    • 12.2.4. AstraZeneca PLC
    • 12.2.5. Boehringer Ingelheim
    • 12.2.6. GlaxoSmithKline plc
    • 12.2.7. Pfizer Inc.
    • 12.2.8. Novartis AG
    • 12.2.9. Roche Holding AG
    • 12.2.10. Daiichi Sankyo Company, Limited
    • 12.2.11. Sun Pharmaceutical Industries Ltd.
    • 12.2.12. Dr. Reddy's Laboratories Ltd.
    • 12.2.13. Aurobindo Pharma Limited
    • 12.2.14. Lupin Limited
    • 12.2.15. Medtronic
    • 12.2.16. B. Braun Melsungen AG
    • 12.2.17. F. Hoffmann-La Roche
    • 12.2.18. Abbott Laboratories
    • 12.2.19. Insulet Corporation
    • 12.2.20. Torrent Pharmaceuticals Limited
    • 12.2.21. Takeda Pharmaceuticals Limited
    • 12.2.22. Acon Laboratories, Inc.
    • 12.2.23. Akros Pharma
    • 12.2.24. Adocia
    • 12.2.25. Amgen
    • 12.2.26. Bayer AG
    • 12.2.27. Biocon
    • 12.2.28. Becton, Dickson, and Company
    • 12.2.29. Peptron
    • 12.2.30. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us